Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by GenSight Biologics

News headline image
GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Confirms Definitive Full-Year 2025 Consolidated Financial Results Are in Line with Estimates
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025
From GenSight Biologics
Via Business Wire
News headline image
The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Provides Updates about GS010/LUMEVOQ® Early Access Programs and the Ongoing REVISE Study
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Announces Regulatory Approval for GS010/LUMEVOQ® REVISE Dose-Ranging Study in France
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Announces Regulatory Authorizations for Individual Patient Expanded Access Treatment with GS010/LUMEVOQ® in the US
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Reports Cash Position as of September 30, 2025
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Reports Interim Financial Results for the First Half of 2025
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Reports Cash Position as of June 30, 2025
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Annual General Meeting on May 13, 2025
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business Update
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2025
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Reports End-of-Year Cash Position and Provides Business Update
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Launches Newsletter for Retail Investors
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Appoints William Monteith to its Board of Directors
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics: Annual General Meeting on May 29, 2024
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Announces the Filing of its 2023 Universal Registration Document
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Announces its 2024 Financial Calendar
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration
From GenSight Biologics
Via Business Wire
News headline image
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024
From GenSight Biologics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.